Stocks making the biggest moves premarket: Centene, JPMorgan, Cava and more

Major bank stocks, including JPMorgan and Bank of America, saw modest gains after announcing dividend hikes and buybacks post-Fed stress tests. Conversely, Centene shares plummeted 30% after withdrawing its 2025 guidance due to lower health insurance marketplace enrollment and rising Medicaid costs, projecting a ~$2.75/share adjusted EPS shortfall. Meanwhile, Verint Systems surged 10% on reported acquisition talks with Thoma Bravo, and Rigetti Computing and Cava also rose following positive analyst initiations.

Analysis

The pre-market session reveals starkly divergent single-stock narratives, highlighted by a severe operational setback at Centene (CNC). The managed care company's shares plunged 30% after it withdrew its 2025 guidance, citing lower-than-expected enrollment in key health insurance marketplaces and projecting a material adjusted earnings reduction of approximately $2.75 per share. This revision, compounded by ongoing pressure from higher medical costs in its Medicaid business, points to a fundamental deterioration in its near-term outlook. In contrast, M&A speculation drove Verint Systems (VRNT) up 10% following reports of acquisition talks with private equity firm Thoma Bravo. The banking sector, including JPMorgan (JPM) and Bank of America (BAC), saw modest gains of less than 1% as they announced dividend hikes following the Fed's stress tests, a move that signals capital strength but was likely priced in by the market. Finally, analyst initiations provided catalysts for two growth-oriented names: Rigetti Computing (RGTI) rose nearly 2% on an overweight rating from Cantor Fitzgerald, which set a $15 price target based on the long-term potential of quantum computing, while Cava (CAVA) gained 2% after KeyBanc initiated with an overweight rating, citing its unique market position and comparing its growth potential to Chipotle.

Key Decisions for Investors

• Re-evaluate long positions in Centene (CNC) due to the significant uncertainty created by its 2025 guidance withdrawal and the dual pressures of declining enrollment and rising medical costs.
• For event-driven investors, monitor Verint Systems (VRNT) for confirmation of a deal with Thoma Bravo, as the current stock price may not fully capture a potential acquisition premium.
• View the announced dividend hikes from major banks as confirmation of balance-sheet health, but recognize the muted stock reaction suggests this positive news was largely anticipated and may not drive near-term outperformance.
• Consider the new overweight ratings on Rigetti (RGTI) and Cava (CAVA) as entry points for long-term, speculative growth theses, while acknowledging the nascent stage and associated risks of their respective industries.